Genetic foundations of pain;Bases genéticas del dolor

Revista de la Sociedad Espanola del Dolor

Volumn 11, Issue 7, 2004, Pages 444-451

  Armero, P ^a,b,d   Muriel, C ^a,d   Santos, J ^a,d   Sanchez Montero F J ^a,d   Rodriguez R E ^c,d   González Sarmiento, Rogelio ^b,d  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Depto de Bioquim y Biol Molecular

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Genes; Mutation; Pain; Polymorphism

Indexed keywords

FAMILIAL HEMIPLEGIC MIGRAINE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HEREDITY; HUMAN; NOCICEPTION; PAIN; REVIEW;

EID: 13244296825     PISSN: 11348046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. MacFarlane BV, Wright A, O'Callaghan J, et al. Chronic neuropathic pain and its control by drugs. Pharmacol Ther 1997; 77: 1-19.
2. Clark JW, Bindra D. Individual differences in pain thresholds. Can J Psychol 1956; 10: 69-76.
3. Wolff BB, Jarvik ME. Relationship between superficial and deep somatic thresholds of pain with a note on handedness. Am J Psychol 1964; 77: 589-99.
4. Woodrow KM, Friedman GD, Siegelaub AB, et al. Pain tolerance: differences according to age, sex and race. Psychosom Med 1972; 34: 548-56.
5. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-86.
6. Chapman CR, Hill HF, Saeger L, et al. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain 1990; 43: 47-55.
7. MacGregor AJ, Griffiths GO, Baker J, et al. Determinants of pressure pain threshold in adult twins: evidence that shared environmental influences predominate. Pain 1997; 73: 253-7.
8. Peroutka SJ. Genetic basis of migraine. Clin Neurosci 1998; 5: 34-7.
9. Kaplan DR, Hempstead BL, Martin-Zanca D, et al. The Trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991; 252: 554-8.
10. Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996; 13: 485-8.
11. Indo, Y. Molecular basis of congenital insensitivity to pain with anhidrosis (C1PA): Mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mut 2001; 18: 462-71.
12. Orphoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episode ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87: 543-52.
13. Ducros A, Denier C, Joutel A, et al. Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia. Am J Hum Genet 1999; 64: 89-98.
14. De Fusco M, Marconi R, Silvestre L, et al. Haploinsufficiency of ATP1 A2 encoding the Na+/K+ pump alpha 2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33: 192-6.
15. May A, Ophoff RA, Terwindt GM, et al. Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Hum Genet 1995; 96: 604-8.
16. Noble-Topham SE, Dyment DA, Cader MZ, et al. Migraine with aura is not linked to the FHM gene CACNL1 A4 or the chromosomal region, 19p13. Neurology 2002; 59: 1099-101.
17. Hori T, Oka T, Hosoi M, et al. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann N Y Acad Sci 1998; 840: 269-81.
18. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic artritis. J Clin Invest 1998; 102: 1369-76.
19. Rainero I, Salani G, Valfre W, et al. Absence of linkage between the interleukin-6 gene (-174 G/C) polymorphism and migraine. Neurosci Lett 2003; 343: 155-8.
20. Cunha FQ, Ferreira SH. Peripheral hyperalgesic cytokines. Adv Exp Med Biol 2003; 521: 22-39.
21. Hayes P, Meadows HJ, Gunthorpe MJ, et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2000; 88: 205-15.
22. Mayer P, Hollt V. Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 2001; 9: 167-77.
23. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Nat Acad Sci 1998; 95: 9608-13.
24. Grandy DK, Marchionni MA, Makam H, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Nat Acad Sci 1989; 86: 9762-6.
25. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphism in the dopamine D2 receptor gene and their relationships to strial dopamine receptor density of healthy volunteers. Molec Psychiat 1999; 4: 290-6.
26. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Nco1 alleles. Neurology 1997; 49: 201-6.
27. Sheperd G, Lea RA, Hutchins C, et al. Dopamine receptor genes and migraine with and without aura: an association study. Headache 2002; 42: 346-51.
28. Giros B, El Mestikawy S, Godinot N, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec Pharm 1992; 42: 383-90.
29. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20.
30. Cook EH Jr, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993-8.
31. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-3.
32. Emin Erdal M, Herken H, Yilmaz M, et al. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res 2001; 94: 193-6.
33. Lesch KP, Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental and neurodegenerative disorders? Biol Psychiatry 1998; 44: 179-92.
34. Yilmaz M, Erdal ME, Herke H, et al. Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci 2001; 186: 27-30.
35. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996; 29: 335-56.
36. Isaacson JS, Solis JM, Nicoll RA. Local and diffuse synaptic actions of GABA in the hippocampus. Neuron 1993; 10: 165-75.
37. Ng CH, Ong WY. Increased expression of gamma-aminobutyric acid transporters GAT-1 and GAT-3 in the spinal trigeminal nucleus after facial carrageenan injections. Pain 2001; 92: 29-40.
38. McCarson KE, Enna SJ. Nociceptive regulation of GABA(B) receptor gene expression in rat spinal cord. Neuropharmacology 1999; 38: 1767-73.
39. Ugarte SD, Homanics GE, Firestone LL, Hammond DL. Sensory thresholds and the antinociceptive effects of GABA receptor agonists in mice lacking the beta3 subunit of GABA(A) receptor. Neuroscience 2000; 95: 795-806.
40. Peters HC, Kammer G, Volz A, et al. Mapping, genomic structure, and polymorphisms of the human GABABR1 receptor gene: evaluation of its involvement in idiopathic generalized epilepsy. Neurogenetics 1998; 2: 47-54.
41. Costigan M, Woolf CJ. No DREAM, no pain: closing the spinal gate. Cell, 2002; 108: 297-300.
42. Hai-Ying MC, Graham MP, Steven RL, et al. DREAM is a critical transcriptional repressor for pain modulation. Cell 2002; 108: 31-43.
43. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 1992; 32: 297-311.
44. Meller ST, Dykstra C, Gebhrat GF, et al. Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-d-aspartate produced facilitation of the nociceptive tail-flick. Eur J Pharmacol 1992; 214: 93-6.
45. Meller ST, Pechman PS, Gebhart TJ, et al. Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in rat. Neuroscience 1992; 50: 7:10.
46. Yamamoto T, Shimoyama N, Mizuguchi T. Nitric oxide synthase inhibitor blocks spinal sensitization induced by formalin injection into the rat paw. Anesth Analg 1993; 77: 886-90.
47. Mattson P, Bjelfman C, Lundberg PO, et al. Cytochrome P450 2D6 and glutathione-S-transferase M1 genotypes and migraine. Eur J Clin Invest 2000; 30: 367-71.
48. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278: 1165-74.
49. Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-95.
50. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
51. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8.
52. Kusumi M, Ishhizaki K, Kowa H, et al. Glutathione-S-transferase polymorphisms: susceptibility to migraine without aura. Eur Neurol 2003; 49: 218-22.